Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 7/10/2025

Management of Type 2 Diabetes

Introduction to SGLT2 Inhibitors

  • SGLT2 inhibitors, such as dapagliflozin (Farxiga), are strongly recommended for patients with type 2 diabetes who have kidney disease, as they significantly reduce kidney disease progression, cardiovascular events, and promote weight loss, according to the American Diabetes Association 1
  • Dapagliflozin can be used as monotherapy or add-on to other diabetes medications, as recommended by the American Diabetes Association 1

Renal Protection

  • SGLT2 inhibitors provide significant renal protection regardless of baseline kidney function, with a reduction in kidney disease progression by up to 44% in patients with CKD, as stated by the National Kidney Foundation 1
  • Dapagliflozin is strongly recommended for renal protection regardless of glycemic control needs in patients with T2DM and CKD (eGFR 20-60 mL/min/1.73m² and/or albuminuria), according to the American Diabetes Association 1
  • Empagliflozin reduces kidney disease progression by 28% in patients with CKD, including those with eGFR as low as 20 mL/min/1.73 m², and may be beneficial for cardiovascular protection, as reported in the Kidney International journal 2
  • Dapagliflozin demonstrated significant benefits in the DAPA-CKD trial with a 39% reduction in the primary composite outcome (HR 0.61 [95% CI 0.51-0.72]) and a renal composite outcome reduction of 44% (HR 0.56 [95% CI 0.45-0.68]; p<0.001) 3

Cardiovascular Protection

  • Dapagliflozin demonstrated cardiovascular safety in the DECLARE-TIMI 58 trial, with a reduction in hospitalization for heart failure (HR 0.73 [95% CI 0.61-0.88]), as reported by the American Heart Association 4
  • SGLT2 inhibitors, such as empagliflozin and dapagliflozin, show significant benefits in reducing heart failure hospitalizations (empagliflozin: HR 0.65 [95% CI 0.50-0.85]; dapagliflozin: HR 0.73 [95% CI 0.61-0.88]), with a class effect for patients with heart failure (with reduced or preserved ejection fraction) 5
  • The European Society of Cardiology recommends empagliflozin in patients with established cardiovascular disease who need reduction in cardiovascular mortality, given its stronger reduction in cardiovascular death (HR 0.62 [95% CI 0.49-0.77]) compared to dapagliflozin (HR 0.98 [95% CI 0.82-1.17]) 5, 6

Weight Loss

  • Dapagliflozin consistently produces weight loss of 1-2 kg over 24 weeks, with weight reduction maintained in long-term studies up to 2-4 years, as stated by the American Diabetes Association 1
  • SGLT2 inhibitors provide consistent weight reduction benefits alongside glycemic control in patients with T2DM needing weight loss, according to the Obesity Society 1

Treatment Guidelines

  • Consider dapagliflozin as part of a treatment plan addressing both glycemic and weight goals in patients with T2DM without cardiovascular/renal disease, as recommended by the American Diabetes Association 1
  • Starting dose: 10 mg once daily for patients with eGFR ≥45 mL/min/1.73m², with no dose adjustment needed based on age, gender, race, or body weight, as stated by the FDA 1
  • SGLT2 inhibitors can be initiated at eGFR ≥20 mL/min/1.73m², but are contraindicated in patients with eGFR <15 mL/min/1.73m² or in those on dialysis, as recommended by KDIGO 2022 guidelines and supported by the DAPA-CKD trial 3, 7
  • Dapagliflozin should be continued as long as tolerated, even if eGFR falls below 20 mL/min/1.73 m², until kidney replacement therapy is initiated, according to KDIGO 2022 guidelines 7

Monitoring and Adverse Effects

  • Patients on SGLT2 inhibitors should be monitored for signs of volume depletion, especially when combined with diuretics, and for signs of ketoacidosis, particularly in insulin-deficient patients 8
  • Genital mycotic infections are a common adverse effect of SGLT2 inhibitors, affecting 6% of patients compared to 1% with placebo, and can be mitigated with proper genital hygiene 8
  • Diabetic ketoacidosis (DKA) is a rare but serious risk, especially in insulin-deficient patients, according to Diabetes Care 9
  • There is a risk of volume depletion with SGLT2 inhibitors; monitor volume status and blood pressure, particularly in patients who are ill or fasting, as advised by the Journal of the American College of Cardiology 10

Recommendations from Guideline Societies

  • The American Diabetes Association recommends that empagliflozin should not be initiated in patients with eGFR less than 45 mL/min/1.73 m² for glycemic control purposes, but may be continued at lower eGFR levels for cardiovascular and renal protective effects 9, 8
  • The European Association for the Study of Diabetes recommends that empagliflozin may be continued at lower eGFR levels for cardiovascular and renal protective effects, but with careful monitoring of renal function and volume status 8, 2
  • The American College of Cardiology suggests that the benefits of empagliflozin for cardiovascular protection may outweigh risks even at lower eGFR levels, but with careful consideration of individual patient factors 2
  • The KDIGO 2022 guidelines recommend SGLT2 inhibitors for patients with T2D and CKD to reduce CKD progression, with benefits observed regardless of diabetes status 7, 3
  • The American College of Cardiology recommends choosing empagliflozin 10-25mg daily for patients with established cardiovascular disease and need for CV mortality reduction 6

REFERENCES